Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.67 |
| ▸ | ANPEP | P15144 | 8/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542253 | 1.00 | MMP2 (0.67) | MMP2ANPEPATMTSHRALDH1A1 | |
| SCHEMBL993099 | 1.00 | MMP2 (0.67) | MMP2ANPEPATMTSHRALDH1A1 | |
| SCHEMBL3784082 | 0.82 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1 | |
| SCHEMBL5494889 | 0.82 | MMP2 (0.67) | MMP2ANPEPATMTSHRALDH1A1 | |
| SCHEMBL10027149 | 0.82 | MMP2 (0.67) | MMP2ANPEPATMTSHRALDH1A1 | |
| SCHEMBL10027150 | 0.82 | MMP2 (0.67) | MMP2ANPEPATMTSHRALDH1A1 | |
| SCHEMBL3783080 | 0.82 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1 | |
| SCHEMBL10793356 | 0.82 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1 | |
| SCHEMBL3783083 | 0.82 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1 | |
| SCHEMBL3789111 | 0.82 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017035417-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| US-8933065-B2 | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2262764-B1 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | UNIV NORTH CAROLINA (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| EP-2415766-A1 | METHOD FOR MANUFACTURING BENZODIAZEPINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2011-01-27 | — | — | US | disclosed |
| EP-2262764-A2 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | The University of North Carolina At Chapel Hill (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009145816-A2 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | GABRA5, CYP3A5, GABRA1 | MMP2 4450/4885ANPEP 4090/4885ATM 3600/4885 |
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, GBA1 | MMP2 2322/4885ANPEP 379/4885ATM 3777/4885 |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | LPXN, CACNA1B, PMP22 | MMP2 430/4885ANPEP 18/4885ATM 4635/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MMP2 487/4885ANPEP 3847/4885ATM 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.